Argus raised the firm’s price target on Novo Nordisk to $115 from $110 and keeps a Buy rating on the shares. The company has a robust new product pipeline that includes Phase 3 candidates such as new formulations of its blockbuster GLP-1 treatment, semaglutide, for diabetes and obesity, combination obesity therapies that include semaglutide, as well as new semaglutide indications for Alzheimer’s disease and non-alcoholic steatohepatitis and new drugs for hemophilia, sickle cell disease, and cardiovascular disease, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Cantor starts Novo Nordisk with Overweight on obesity growth runway
- Novo Nordisk initiated with an Overweight at Cantor Fitzgerald
- Compounded Wegovy Matters Sink Novo Nordisk (NYSE:NVO)
- Eli Lilly (NYSE:LLY) Pops Up after Beating Novo Nordisk in Weight Loss
- Lilly’s Mounjaro more effective than Ozempic for weight loss in study, CNBC says